MARKET

ESPR

ESPR

Esperion Therape
NASDAQ
1.490
-0.090
-5.70%
After Hours: 1.490 0 0.00% 19:54 12/08 EST
OPEN
1.570
PREV CLOSE
1.580
HIGH
1.595
LOW
1.480
VOLUME
2.89M
TURNOVER
0
52 WEEK HIGH
7.41
52 WEEK LOW
0.7000
MARKET CAP
169.44M
P/E (TTM)
-0.6295
1D
5D
1M
3M
1Y
5Y
Why Is Catalyst (CPRX) Up 16.2% Since Last Earnings Report?
NASDAQ · 1d ago
Weekly Report: what happened at ESPR last week (1127-1201)?
Weekly Report · 5d ago
Weekly Report: what happened at ESPR last week (1120-1124)?
Weekly Report · 11/27 12:11
JP Morgan bullish on six Big Biotechs, rates nine others neutral or lower
Jp morgan bullish on six big biotechs, rates nine others neutral or lower. Insmed, denali, immunocore, crinetics, mirum and biocryst among those rated overweight. Investment bank was less keen on cervel therapeutics, alkermes and esperion.
Seeking Alpha · 11/25 21:32
JP Morgan Reinstates Neutral on Esperion Therapeutics
Benzinga · 11/20 13:26
Weekly Report: what happened at ESPR last week (1113-1117)?
Weekly Report · 11/20 12:07
Analyst Expectations for Esperion Therapeutics's Future
Esperion therapeutics has 4 analysts rating the stock. These 4 analysts have an average price target of $15.25 versus the current price of $0.9199. Esperion therapeutics has seen an increase in analyst ratings over the past 3 months.
Benzinga · 11/13 18:00
HC Wainwright & Co. Reiterates Buy on Esperion Therapeutics, Maintains $22 Price Target
Benzinga · 11/13 16:19
More
About ESPR
Esperion Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). The Company's bempedoic acid and the bempedoic acid / ezetimibe combination tablets are oral, once-daily, non-statin, LDL-C lowering medicines for patients with atherosclerotic cardiovascular disease (ASCVD), or heterozygous familial hypercholesterolemia (HeFH). The Company's products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. Its NEXLETOL is an ATP Citrate Lyase (ACL), inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NEXLIZET and NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine.

Webull offers Esperion Therapeutics Inc stock information, including NASDAQ: ESPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ESPR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ESPR stock methods without spending real money on the virtual paper trading platform.